General
Preferred name
SULINDAC
Synonyms
Clinoril ()
MK-231 ()
SULINDAC SULFOXIDE ()
Arthrocine ()
Sulindaco ()
Artribid ()
NSC-757344 ()
Sulindac-d3 ()
P&D ID
PD001740
CAS
38194-50-2
32004-68-5
9000-14-0
Tags
available
prodrug
drug
Approved by
FDA
First approval
1978
Drug indication
rheumatic disease
Rheumatoid arthritis
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Useful in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene. The exact mechanism of its NSAID properties is unknown, but it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis. Recent report suggests potential use for cystic fibrosis .
DESCRIPTION
Useful in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene. It has COX inhibitory activity, but the full details of its anti-inflammatory and and proapoptotic (anti-tumour) mechanisms remain to be resolved. Antagonism of RXRα has been implicated in its apoptosis-promoting effects in cancer cells . Recent report suggests potential use for cystic fibrosis .
(GtoPdb)
PRICE
29
DESCRIPTION
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2].
DESCRIPTION
COX inhibitor; Anti-inflammatory
(LOPAC library)
DESCRIPTION
Cyclooxygenase inhibitor (following metabolism to sulindac sulfide)
(Tocriscreen Total)
DESCRIPTION
Sulindac (Sulindac sulfoxide) is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
24
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
45
Molecular Weight
356.09
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
2
cLogP
4.37
TPSA
54.37
Fraction CSP3
0.15
Chiral centers
1.0
Largest ring
6.0
QED
0.89
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
COX
Pathway
Autophagy
Immunology/Inflammation
Neuroscience
NF-¦ÊB
MOA
COX inhibitor
ABCC1 Expression Enhancers
ABCC3 Expression Enhancers
Non-Steroidal Antiinflammatory Drugs
NF-kappaB (NFKB) Activation Inhibitors
Member status
member
Target
NF-κB
PD-1/PD-L1
Therapeutic Class
Antiinflammatory Agents
Source data
